Literature DB >> 24657270

Weight variation over time and its relevance among multidrug-resistant tuberculosis patients.

Kocfa Chung-Delgado1, Alejandro Revilla-Montag1, Sonia Guillén-Bravo1, Antonio Bernabe-Ortiz2.   

Abstract

OBJECTIVES: We aimed to assess the variation in patient body weight over time according to the treatment outcome among multidrug-resistant tuberculosis (MDR-TB) cases.
METHODS: This was a retrospective cohort study. The data of patients commencing MDR-TB therapy were analyzed. Data were collected from different public TB treatment facilities located in peri-urban areas to the south of Lima, Peru. The outcome was patient body weight (kilograms) from treatment commencement, measured monthly. A random effects model was fitted using robust standard errors to calculate 95% confidence intervals.
RESULTS: Of a total of 1242 TB cases, 243 (19.6%) were MDR-TB. Only 201 cases were included in the analysis; 127 (63.2%) were males and the mean patient age was 33.6 (standard deviation 16.2) years. Weight changes over time among the patients who were cured differed from changes in those who died during therapy (p<0.001). Weight curve divergence was important at the end of the third, fourth, and fifth treatment months: on average, the weight difference was 2.18kg (p<0.001), 3.27kg (p=0.007), and 3.58kg (p=0.03), respectively, when cured patients were compared to those who died.
CONCLUSIONS: Our results show that weight variation during treatment can be a useful surrogate for the treatment outcome, specifically death during therapy. MDR-TB patients with weight loss should be followed more closely, as they are at greater risk of death.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Multidrug-resistant tuberculosis; Treatment outcome; Tuberculosis; Weight

Mesh:

Substances:

Year:  2014        PMID: 24657270     DOI: 10.1016/j.ijid.2014.01.001

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.

Authors:  Lauren S Peetluk; Peter F Rebeiro; Marcelo Cordeiro-Santos; Afranio Kritski; Bruno B Andrade; Betina Durovni; Solange Calvacante; María B Arriaga; Megan M Turner; Marina C Figueiredo; Valeria C Rolla; Timothy R Sterling
Journal:  J Infect Dis       Date:  2020-04-07       Impact factor: 5.226

2.  Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Joel Philip Samuels; Aashna Sood; Jonathon R Campbell; Faiz Ahmad Khan; James Cameron Johnston
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

3.  Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study.

Authors:  Alhassane Diallo; Boubacar Djelo Diallo; Lansana Mady Camara; Lucrèce Ahouéfa Nadège Kounoudji; Boubacar Bah; Fulgence N'Zabintawali; Miguel Carlos-Bolumbu; Mamadou Hassimiou Diallo; Oumou Younoussa Sow
Journal:  BMC Infect Dis       Date:  2020-04-28       Impact factor: 3.090

4.  Time to poor treatment outcome and its predictors among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara region, Ethiopia: retrospective cohort study.

Authors:  Daniel Bekele Ketema; Kindie Fentahun Muchie; Asrat Atsedeweyn Andargie
Journal:  BMC Public Health       Date:  2019-11-08       Impact factor: 3.295

5.  BIOIMPEDANCE MARKERS AND TUBERCULOSIS OUTCOME AMONG HIV-INFECTED PATIENTS.

Authors:  Raúl Montalvo; Antonio Bernabe-Ortiz; Daniela E Kirwan; Robert H Gilman
Journal:  Afr J Infect Dis       Date:  2018-06-18

6.  Predictors of mortality in multidrug-resistant tuberculosis patients from Brazilian reference centers, 2005 to 2012.

Authors:  Regina Gayoso; Margareth Dalcolmo; José Ueleres Braga; Draurio Barreira
Journal:  Braz J Infect Dis       Date:  2018-08-06       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.